A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors.

@article{Hong2012AMP,
  title={A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors.},
  author={David S. Hong and Daniel W. Bowles and Gerald Steven Falchook and Wells A. Messersmith and Goldy C George and Cindy L O'bryant and Alex C H Vo and Kevin Klucher and R. Scott Herbst and Stephan Eckhardt and Scott Thomas Peterson and Diana Felice Hausman and Razelle Kurzrock and Antonio J. Jimeno},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2012},
  volume={18 15},
  pages={
          4173-82
        }
}
PURPOSE The objectives of the study were to evaluate the maximum tolerated dose (MTD), safety, pharmacodynamics, pharmacokinetics, and antitumor activity of PX-866 in patients with incurable cancers. EXPERIMENTAL DESIGN This was a phase I, open-label, dose-escalation study. Drug was administered orally once per day either on an intermittent (arm 1; days 1-5 and 8-12 of a 28-day cycle) or continuous (arm 2; days 1-28 of a 28-day cycle) schedule. Additional patients were treated at the arm 2… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 73 CITATIONS, ESTIMATED 54% COVERAGE

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2015
VIEW 8 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours

  • British Journal of Cancer
  • 2013
VIEW 6 EXCERPTS
CITES BACKGROUND, METHODS & RESULTS
HIGHLY INFLUENCED

First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2014
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2012
2019

CITATION STATISTICS

  • 6 Highly Influenced Citations

  • Averaged 6 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 43 REFERENCES

Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2012
VIEW 1 EXCERPT

BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study [abstract

D B Juric, J Rodon, +3 authors J Berlin
  • Proceedings of the 103rd Annual Meeting of the Amer icanAssociation forCancerResearch; 2012Mar 31–Apr 4;Chicago, IL. Philadelphia (PA): AACR;
  • 2012
VIEW 1 EXCERPT

Molecular pharmacology and antitumor activity of PX-866, a First-in-Human Trial of PX-866 www.aacrjournals.org Clin Cancer Res

NT Ihle, R Williams, +3 authors G Paine-Murrieta
  • OF9 Research. on April
  • 2012
VIEW 1 EXCERPT

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
VIEW 1 EXCERPT

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
VIEW 3 EXCERPTS

17Hydroxy-PX-866, the primary metabolite of PX-866, an irreversible, pan-isoform inhibitor of phosphatidylinositol-3 (PI3) kinase, has increased activity in biochemical and cellular assays [abstract

K Klucher, A Vo, +3 authors J Millard
  • AACR Special Conference on Targeting PI3K/mTOR Signaling in Cancer;
  • 2011
VIEW 3 EXCERPTS